NCT06732232View on ClinicalTrials.gov

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 12, 2027

Study Completion Date

December 12, 2027

Conditions
RelapsedRefractoryMultiple Myeloma
Interventions
DRUG

CD19/CD20/BCMA CAR-T

CD19/CD20/BCMA CAR T therapy

Trial Locations (1)

Unknown

RECRUITING

China, Shanghai Mengchao Cancer Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Cell Therapy Group Co.,Ltd

INDUSTRY